These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Pedrosa I; Alsop DC; Rofsky NM Cancer; 2009 May; 115(10 Suppl):2334-45. PubMed ID: 19402070 [TBL] [Abstract][Full Text] [Related]
4. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720 [TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547 [TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. de Lussanet QG; Backes WH; Griffioen AW; Padhani AR; Baeten CI; van Baardwijk A; Lambin P; Beets GL; van Engelshoven JM; Beets-Tan RG Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1309-15. PubMed ID: 16125874 [TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. Atkin G; Taylor NJ; Daley FM; Stirling JJ; Richman P; Glynne-Jones R; d'Arcy JA; Collins DJ; Padhani AR Br J Surg; 2006 Aug; 93(8):992-1000. PubMed ID: 16673354 [TBL] [Abstract][Full Text] [Related]
8. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis. Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761 [TBL] [Abstract][Full Text] [Related]
9. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Padhani AR; Leach MO Abdom Imaging; 2005; 30(3):324-41. PubMed ID: 15688112 [TBL] [Abstract][Full Text] [Related]
10. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). De Bazelaire C; Rofsky NM; Duhamel G; Michaelson MD; George D; Alsop DC Acad Radiol; 2005 Mar; 12(3):347-57. PubMed ID: 15766695 [TBL] [Abstract][Full Text] [Related]
12. Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. Palmowski M; Schifferdecker I; Zwick S; Macher-Goeppinger S; Laue H; Haferkamp A; Kauczor HU; Kiessling F; Hallscheidt P Eur J Radiol; 2010 Jun; 74(3):e176-80. PubMed ID: 19540690 [TBL] [Abstract][Full Text] [Related]
13. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study. Mendichovszky IA; Cutajar M; Gordon I Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588 [TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. Padhani AR J Magn Reson Imaging; 2002 Oct; 16(4):407-22. PubMed ID: 12353256 [TBL] [Abstract][Full Text] [Related]
15. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268 [TBL] [Abstract][Full Text] [Related]
16. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563 [TBL] [Abstract][Full Text] [Related]
17. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299 [TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440 [TBL] [Abstract][Full Text] [Related]